InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed’s latest milestones including the latest on the Phase 2 clinical trial of an investigational cannabinol cream for the treatment of epidermolysis bullosa. He also speaks about the company’s other development programs including INM-088, the CBN formulation for glaucoma in preclinical development, and the neurodegenerative disease program. InMed’s recent neurodegenerative disease study showed neuroprotective effects in a population of neurons and enhanced neuronal function. Two cannabinoid analogs have been selected to advance to in vivo studies.
Lastly, Eric Adams talks about the company’s subsidiary, BayMedica, and the recent increase of sales of its bioidentical rare cannabinoids for the health and wellness industry.
